The Study of Drug SCT510A in Patients With Wet Age-related Macular Degeneration (wAMD)
Status:
Not yet recruiting
Trial end date:
2022-10-31
Target enrollment:
Participant gender:
Summary
Multicenter ，open-label, multi-dose study to evaluate the safety and tolerability in patients
with wAMD treated with intravitreal recombinant humanized anti-VEGF monoclonal
antibody（SCT510A）